Walvax BioTech Financial Flexibility Index
Walvax BioTech financial flexibility index. Walvax BioTech (300142) has a Financial Flexibility Index of 0.08x as of September 2025. Free cash flow of CN¥182.25 Million (operating CF CN¥-33.52 Million minus capex CN¥215.77 Million) represents 0% of total liabilities (CN¥2.31 Billion). See how much free cash does Walvax BioTech generate to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Walvax BioTech (2007–2025)
Financial flexibility index of Walvax BioTech from 2007 to 2025. Historical Financial Flexibility Index trend for Walvax BioTech across 19 annual periods. Check Walvax BioTech cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Walvax BioTech Financial Flexibility Index by Year (2007–2025)
Walvax BioTech financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Walvax BioTech. For the full cash flow conversion analysis, see how efficiently does Walvax BioTech generate cash.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.44x | CN¥1.00 Billion | CN¥494.37 Million | CN¥2.26 Billion | ▼ -9.8% |
| 2024 | 0.49x | CN¥1.59 Billion | CN¥1.04 Billion | CN¥3.22 Billion | ▼ -0.5% |
| 2023 | 0.50x | CN¥2.08 Billion | CN¥1.13 Billion | CN¥4.19 Billion | ▼ -6.0% |
| 2022 | 0.53x | CN¥2.29 Billion | CN¥1.20 Billion | CN¥4.35 Billion | ▲ +7.2% |
| 2021 | 0.49x | CN¥1.81 Billion | CN¥705.28 Million | CN¥3.68 Billion | ▲ +69.9% |
| 2020 | 0.29x | CN¥521.32 Million | CN¥114.19 Million | CN¥1.80 Billion | ▼ -5.4% |
| 2019 | 0.31x | CN¥413.84 Million | CN¥62.02 Million | CN¥1.35 Billion | ▲ +274.5% |
| 2018 | 0.08x | CN¥162.09 Million | CN¥-65.23 Million | CN¥1.98 Billion | ▼ -40.9% |
| 2017 | 0.14x | CN¥320.93 Million | CN¥-10.13 Million | CN¥2.32 Billion | ▲ +141.8% |
| 2016 | 0.06x | CN¥160.30 Million | CN¥-89.94 Million | CN¥2.80 Billion | ▼ -5.2% |
| 2015 | 0.06x | CN¥195.34 Million | CN¥-69.41 Million | CN¥3.23 Billion | ▼ -4.6% |
| 2014 | 0.06x | CN¥174.46 Million | CN¥-65.93 Million | CN¥2.76 Billion | ▼ -24.5% |
| 2013 | 0.08x | CN¥267.94 Million | CN¥-121.73 Million | CN¥3.20 Billion | ▼ -75.3% |
| 2012 | 0.34x | CN¥434.25 Million | CN¥78.38 Million | CN¥1.28 Billion | ▼ -65.6% |
| 2011 | 0.99x | CN¥289.54 Million | CN¥91.98 Million | CN¥293.62 Million | ▲ +70.7% |
| 2010 | 0.58x | CN¥251.53 Million | CN¥86.71 Million | CN¥435.52 Million | ▼ -22.2% |
| 2009 | 0.74x | CN¥156.94 Million | CN¥82.18 Million | CN¥211.43 Million | ▲ +537.6% |
| 2008 | 0.12x | CN¥23.70 Million | CN¥-5.69 Million | CN¥203.54 Million | ▼ -53.6% |
| 2007 | 0.25x | CN¥50.10 Million | CN¥31.85 Million | CN¥199.86 Million | — |